Compare Amphastar Pharmaceuticals Inc (AMPH) vs Flagstar Bank NA (FLG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Flagstar Bank NA — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Flagstar Bank NA trades at $14.21 (market cap $5.82B). The key difference: Flagstar Bank NA is far larger — about 6.7× Amphastar Pharmaceuticals Inc's market cap, and Flagstar Bank NA pays a 0.29% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | FLG | |
|---|---|---|
Market Cap | $863.95M | $5.82B |
Sector | Health | Financials |
52-Week High | $30.81 | $15.36 |
52-Week Low | $16.87 | $10.72 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 0.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Flagstar Bank (FLG) trades at $13.95, down 1.48% amid a bearish technical signal, though it remains profitable with a net income margin of 2.3% in 2026. Recent Q2 2026 earnings missed estimates, but the company announced a $250 million share repurchase program and continues dividend payments, reflecting confidence in its capital position. The stock trades below book value with a P/B of 0.76, offering a potential margin of safety.
The outlook is mixed: analyst consensus is bullish with a $16.85 price target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of growth initiatives, while downside could stem from further earnings misses or economic headwinds affecting the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →
